We only have this paper's title and publication details.
Read it at the sourcePhase Ib multicenter trial evaluates subcutaneous isatuximab with pomalidomide and dexamethasone in relapsed multiple myeloma, highlighting administration routes.
No takes yet. Share an insight, caveat, or question.
Quach et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: